Healthcare Industry News:  Mylan Laboratories 

Biopharmaceuticals FDA Generics

 News Release - February 6, 2006

Mylan Announces FDA Approval for Cyclobenzaprine Hydrochloride Tablets USP, 5 mg

PITTSBURGH, Feb. 6 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (ANDA) for Cyclobenzaprine Hydrochloride Tablets USP, 5 mg. Cyclobenzaprine Tablets are the AB-rated generic equivalent of McNeil's FlexerilŽ Tablets. U.S. sales for the 5 mg strength of FlexerilŽ were approximately $93 million for the 12-month period ending June 30, 2005, according to IMS Health.

This product will begin shipping immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, visit http://www.mylan.com.


Source: Mylan Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.